KLRK1 and neoplasm: Although their high expression on tumors makes them ideal targets for CAR-T therapy, the presence of these ligands on certain normal or damaged cells raises concerns regarding potential off-tumor toxicity associated with NKG2D CAR-T therapy [15, 16].